MonoSol Rx, the developers of PharmFilm technology and a drug delivery company has announced that the new drug application (NDA) for ondansetron orally dissolving film strip (ODFS) has
Access Pharmaceuticals has announced that the company has received issue notifications from the US Patent and Trademark Office that two US patents relating to MuGard, the company’s approved
NeurogesX has announced that FDA agreed to its proposed study to evaluate Qutenza in patients with post-herpetic neuralgia (PHN) following pretreatment with an FDA approved topical anesthetic.
Roche has announced one year data from the two year Phase III LITHE study. The study demonstrated that a greater proportion of rheumatoid arthritis (RA) patients treated with
FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) voted that Zyprexa (olanzapine), an atypical antipsychotic, is effective and acceptably safe for the acute treatment of schizophrenia or manic or mixed
Transdel Pharmaceuticals and JH Direct have entered into a licensing agreement, providing JH Direct with the exclusive worldwide rights to Transdel’s anti-cellulite cosmeceutical product. Under the agreement, JH
Boehringer Ingelheim presented new data at the Movement Disorder Society’s 13th International Congress of Parkinson’s Disease and Movement Disorders (MDS). The new results confirms high therapeutic benefit of
Metabasis and its partner Merck have announced that AMP protein kinase (AMPK) activators, has yielded a lead candidate that Merck has selected to advance into late preclinical development.
Roche has reported that up to 56% of patients with active rheumatoid arthritis (RA) treated with ACTEMRA for over two years, will achieve disease remission. The new data
MDS Nordion, a provider of medical isotopes and radiopharmaceuticals, has announced that it has commenced the manufacture of CardioGen-82 (Rubidium-82 generators), for Bracco. MDS Nordion has designed and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.